Victória Etges Helfer

Dr. Victória Etges Helfer

Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
BTBruna G. S. Torres
Bruna G. S. Torres
VHVictória Etges Helfer
Victória Etges Helfer
PBPriscila M. Bernardes
Priscila M. Bernardes
AMAlexandre Macedo
Alexandre Macedo
ENElisabet I. Nielsen
Elisabet I. Nielsen
TCTeresa Dalla Costa
Teresa Dalla Costa
Biofilm formation plays an important role in the persistence of pulmonary infections, for example, in cystic fibrosis patients. So far, little is known about the antimicrobial lung disposition in biofilm-associated pneumonia. This study aimed to evaluate, by microdialysis, ciprofloxacin (CIP) penetration into the lungs of healthy and Pseudomonas aeruginosa biofilm-infected rats and to develop a comprehensive model to describe the CIP disposition under both conditions. P. aeruginosa was immobilized into alginate beads and intratracheally inoculated 14 days before CIP administration (20 mg/kg of body weight). Plasma and microdialysate were sampled from different animal groups, and the observations were evaluated by noncompartmental analysis (NCA) and population pharmacokinetic (popPK) analysis. The final model that successfully described all data consisted of an arterial and a venous central compartment and two peripheral distribution compartments, and the disposition in the lung was modeled as a two-compartment model structure linked to the venous compartment. Plasma clearance was approximately 32% lower in infected animals, leading to a significantly higher level of plasma CIP exposure (area under the concentration-time curve from time zero to infinity, 27.3 ± 12.1 μg · h/ml and 13.3 ± 3.5 μg · h/ml in infected and healthy rats, respectively). Despite the plasma exposure, infected animals showed a four times lower tissue concentration/plasma concentration ratio (lung penetration factor = 0.44 and 1.69 in infected and healthy rats, respectively), and lung clearance (CL lung ) was added to the model for these animals (CL lung = 0.643 liters/h/kg) to explain the lower tissue concentrations. Our results indicate that P. aeruginosa biofilm infection reduces the CIP free interstitial lung concentrations and increases plasma exposure, suggesting that plasma concentrations alone are not a good surrogate of lung concentrations.

1 October 2020 in Journal of Chromatography B
Verified
Journal Article
Closed access
FCFernando Carreño
Fernando Carreño
VHVictória Etges Helfer
Victória Etges Helfer
KSKeli Jaqueline Staudt
Keli Jaqueline Staudt
LOLaura Bem Olivo
Laura Bem Olivo
FBFabiano Barreto
Fabiano Barreto
TCTeresa Dalla Costa
Teresa Dalla Costa

1 April 2020 in Schizophrenia Research
Verified
Journal Article
Closed access
FCFernando Carreño
Fernando Carreño
VHVictória Etges Helfer
Victória Etges Helfer
KSKeli Jaqueline Staudt
Keli Jaqueline Staudt
KPKarina Paese
Karina Paese
FMFabíola Schons Meyer
Fabíola Schons Meyer
TCTeresa Dalla Costa
Teresa Dalla Costa

1 October 2020 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
FCFernando Carreño
Fernando Carreño
VHVictória Etges Helfer
Victória Etges Helfer
KSKeli Jaqueline Staudt
Keli Jaqueline Staudt
LOLaura Bem Olivo
Laura Bem Olivo
KPKarina Paese
Karina Paese
TCTeresa Dalla Costa
Teresa Dalla Costa
This study investigated plasma and brain disposition of quetiapine lipid core nanocapsules (QLNC) in naïve and schizophrenic (SCZ-like) rats and developed a semi-mechanistic model to describe changes in both compartments following administration of drug in solution (FQ) or nanoencapsulated. QLNC (1 mg/mL) presented 166 {plus minus} 39 nm, low polydispersity, and high encapsulation (93.0 {plus minus} 1.4%). Model building using experimental data from total and unbound plasma and unbound brain concentrations obtained by microdialysis after administration of single i.v. bolus dose of FQ or QLNC to naïve and SCZ-like rats. A two-compartment model was identifiable both in blood and in brain with a bi-directional drug transport across the blood-brain barrier (CLin and CLout). SCZ-like rats significant decrease in brain exposure with FQ (decrease in CLin) was reverted by QLNC showing that nanocarriers govern quetiapine tissue distribution. Model simulations allowed exploring the potential of LCN for brain delivery. Significance Statement A population approach was used to simultaneously model total and unbound plasma and unbound brain quetiapine concentrations allowing for quantification of the rate and extent of drug’s brain distribution following administration of both free drug in solution or as nanoformulation to naïve and SCZ-like rats. The model-based approach is useful to better understand the possibilities and limitations of this nanoformulation for drug delivering to the brain, opening the opportunity to use this approach to improve SCZ-treatment limited response rates.

4 June 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
ETElizabeth J. Thompson
Elizabeth J. Thompson
AJAngela Jeong
Angela Jeong
VHVictória Etges Helfer
Victória Etges Helfer
VSValentina Shakhnovich
Valentina Shakhnovich
AEAndrea Edginton
Andrea Edginton
TCthe Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Pantoprazole is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease, a condition that disproportionately affects children with obesity. Appropriately dosing pantoprazole in children with obesity requires understanding the body size metric that best guides dosing, but pharmacokinetic (PK) trials using traditional techniques are limited by the need for larger sample sizes and frequent blood sampling. Physiologically‐based PK (PBPK) models are an attractive alternative that can account for physiologic‐, genetic‐, and drug‐specific changes without the need for extensive clinical trial data. In this study, we explored the effect of obesity on pantoprazole PK and evaluated label‐suggested dosing in this population. An adult PBPK model for pantoprazole was developed using data from the literature and accounting for genetic variation in CYP2C19. The adult PBPK model was scaled to children without obesity using age‐associated changes in anatomical and physiological parameters. Lastly, the pediatric PBPK model was expanded to children with obesity. Three pantoprazole dosing strategies were evaluated: 1 mg/kg total body weight, 1.2 mg/kg lean body weight, and US Food and Drug Administration‐recommended weight‐tiered dosing. Simulated concentration–time profiles from our model were compared with data from a prospective cohort study (PAN01; NCT02186652). Weight‐tiered dosing resulted in the most (>90%) children with pantoprazole exposures in the reference range, regardless of obesity status or CYP2C19 phenotype, confirming results from previously published population PK models. PBPK models may allow for the efficient study of physiologic and developmental effects of obesity on PK in special populations where clinical trial data may be limited.

11 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BDBruna Bernar Dias
Bruna Bernar Dias
FCFernando Carreno
Fernando Carreno
VHVictória Etges Helfer
Victória Etges Helfer
PGPriscila Martini Bernardi Garzella
Priscila Martini Bernardi Garzella
DLDaiane Maria Fonseca de Lima
Daiane Maria Fonseca de Lima
TCTeresa Dalla Costa
Teresa Dalla Costa
Biofilms and infectious process may alter free antimicrobial concentrations at the site of infection. Tobramycin (TOB), an aminoglycoside used to treat lung infections caused by Pseudomonas aeruginosa, binds to alginate present in biofilm extracellular matrix increasing its minimum inhibitory concentration (MIC). This work aimed to investigate the impact of biofilm-forming P. aeruginosa infection on TOB lung and epithelial lining fluid (ELF) penetration, using microdialysis, and to develop a population pharmacokinetic (popPK) model to evaluate the probability of therapeutic target attainment of current dosing regimens employed in fibrocystic and non-fibrocystic patients. The popPK model developed has three compartments including the lung. The ELF concentrations were described by a penetration factor derived from the lung compartment. Infection was a covariate in lung volume (V3) and only chronic infection was a covariate in central volume (V1) and total clearance (CL). Simulations of the recommended treatments for acute and chronic infection achieved >90% probability of target attainment (PTA) in the lung with 4.5 mg/kg q24h and 11 mg/kg q24h, respectively, for the most prevalent P. aeruginosa MIC (0.5 mg/mL). The popPK model was successfully applied to evaluate the PTA of current TOB dosing regimens used in the clinic, indicating the need to investigate alternative posology.